[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vasgen-limited” connections=”true” suffix=””]

Vasgens drug discovery platform AbIMP_ (Antibody Inhibitor of Metalloproteinases) are proto-type antibodies that display a high degree of selectivity for their ADAM targets and binds to an epitope comprising of key conserved and variable amino acids spanning the junction between the N-terminal and C-terminal sub-domains, proximal to the catalytic-cleft of the ADAM metalloproteinase domain.